Eesti - eesti - Ravimiamet

astrazeneca ab - felodipiin - toimeainet prolongeeritult vabastav tablett - 10mg 14tk; 10mg 30tk; 10mg 98tk; 10mg 20tk; 10mg 28tk; 10mg 500tk; 10mg 90tk; 10mg 50tk; 10mg 100tk

Eesti - eesti - Ravimiamet

astrazeneca ab - budesoniid - inhalatsioonipulber - 0,2mg 1annus 200annus 1tk; 0,2mg 1annus 100annus 1tk

Eesti - eesti - Ravimiamet

astrazeneca ab - felodipiin - toimeainet prolongeeritult vabastav tablett - 2,5mg 98tk; 2,5mg 28tk; 2,5mg 20tk; 2,5mg 100tk; 2,5mg 50tk; 2,5mg 30tk

Eesti - eesti - Ravimiamet

astrazeneca ab - formoterool - inhalatsioonipulber - 4,5mcg 1annus 60annus 1tk

Eesti - eesti - Ravimiamet

astrazeneca ab - gosereliin - implantaat - 3,6mg 1tk

Eesti - eesti - Ravimiamet

astrazeneca ab - formoterool - inhalatsioonipulber - 9mcg 1annus 60annus 1tk

Eesti - eesti - Ravimiamet

astrazeneca ab - budesoniid - nebuliseeritav suspensioon - 0,25mg 1ml 2ml 20tk

Eesti - eesti - Ravimiamet

astrazeneca ab - budesoniid - inhalatsioonipulber - 0,1mg 1annus 200annus 1tk

Euroopa Liit - eesti - EMA (European Medicines Agency)

astrazeneca ab - selumetinib sulfate - neurofibromatosis 1 - antineoplastilised ained - koselugo as monotherapy is indicated for the treatment of symptomatic, inoperable plexiform neurofibromas (pn) in paediatric patients with neurofibromatosis type 1 (nf1) aged 3 years and above.

Euroopa Liit - eesti - EMA (European Medicines Agency)

astrazeneca ab - dapaglifloksiinpropaandioolmonohüdraat - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - diabeetis kasutatavad ravimid - type 2 diabetes mellitusforxiga is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance. lisaks teiste ravimitega ravi 2. tüüpi diabeedi. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 ja 5. heart failureforxiga is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseaseforxiga is indicated in adults for the treatment of chronic kidney disease.